TL;DR: Proposed 12.5% US tariffs on Australian exports under a Section 301 investigation threaten global supply chains for life-changing hearing technology. Advocates and medical executives warn the tariff will disrupt access to essential cochlear implants manufactured in Sydney.
The Intersection of Trade Policy and Assistive Technology
In July 2026, a major international trade dispute has highlighted the vulnerability of global supply chains for critical disability medical devices. The United States government is preparing to formalize a 12.5 percent tariff on imports from 60 countries, including Australia. This tariff, initiated under a Section 301 investigation, is ostensibly aimed at penalizing countries that the US trade office claims have failed to enforce legal bans on the importation of goods produced with forced labour.
However, Australian manufacturers and international disability advocates warn that these tariffs will impose severe, unintended consequences on individuals with profound hearing loss. Specifically, the tariffs threaten the supply of cochlear implants, which are primarily manufactured by the Australian company Cochlear at its production plants in Macquarie Park, Sydney.
The Real-World Impact of Cochlear Technology
For individuals with severe hearing impairment, access to highly specialized medical devices is essential for maintaining employment, independence, and social connection. The life of Donna Sorkin, a resident of McLean, Virginia, illustrates the transformative nature of this technology.
Sorkin was an early adopter of the Cochlear Nucleus 22 implant, which she received in December 1992 after undergoing surgery at Johns Hopkins University under surgeon John Niparko. At the time, the Australian-made device was the only cochlear implant approved by the US Food and Drug Administration (FDA). The implant completely transformed her life, allowing her to pursue a successful career, including serving as the founding executive director of the American Cochlear Implant Alliance for 14 years.
In contrast, Sorkin’s father, who also suffered from profound adult-onset hearing loss, did not have access to this technology. As a result, he was forced to retire on a medical disability at the age of 52 because he could no longer perform the key requirements of his job. This contrast highlights the critical role that accessible assistive technology plays in preventing premature retirement and supporting individuals with disabilities in the workforce.
The Dispute Over Modern Slavery Protections
The US trade office's justification for the tariff relies on a report alleging that Australia and 53 other countries have failed to establish a US-style legal prohibition on importing products made with forced labour.
The Australian government has strongly defended its regulatory framework. Erin Kelly, the acting trade counsellor at the Australian embassy in Washington, signed a formal written submission arguing that Australia possesses robust, highly effective protections against modern slavery. Kelly pointed out that the US State Department consistently awards Australia top-tier status in its Trafficking in Persons Report, which evaluates national efforts to eliminate human trafficking and forced labour. She argued that there is no evidence to support the claim that the US model is superior, and that any tariff action against Australia is entirely unsupported by the record.
Industry Warnings of Supply Disruptions
Lisa Aubert, the president of Cochlear North America, testified at a public hearing in Washington to request a formal exemption from the tariff. Aubert warned that imposing a 12.5 percent tariff risks causing severe supply chain disruptions for US patients. Because the vast majority of cochlear implants used in the US are manufactured at Cochlear’s plants in Sydney—with others imported from MED-EL in Austria—there is no practical domestic manufacturing alternative in the United States.
Industry groups, including the Business Council of Australia, and other exporters like baby formula maker Bubs Australia, have also submitted appeals. They argue that the tariffs will simply impose substantial, unproductive costs on US consumers, healthcare providers, and businesses, without making any impact on the global reduction of forced labour.
Key Takeaways
- Tariff Threat: A proposed 12.5 percent US tariff on Australian imports threatens to disrupt the supply of life-altering Cochlear implants manufactured in Sydney.
- Employment and Disability: Access to advanced hearing technology prevents premature retirement, as demonstrated by the contrast between Donna Sorkin's career and her father's early medical retirement at 52.
- Regulatory Disputes: The Australian government, via acting trade counsellor Erin Kelly, defends its modern slavery laws, pointing to Australia's top-tier status in the US Trafficking in Persons Report.
- Supply Chain Vulnerability: Cochlear North America President Lisa Aubert warns that because there is no US domestic manufacturer, the tariffs will directly harm patients and disrupt critical medical supply chains.
- Exemption Requests: Major Australian exporters, including Cochlear and Bubs Australia, are actively seeking formal carveouts to protect consumers from rising costs on-offload impacts on consumers.